Bristol Myers Squibb gets 3 years of exclusive AI support for its brain-drug programs

Pathos AI has secured a $55M deal with Tempus AI to create a neurological disease dataset. Bristol Myers Squibb (BMY) leads Pathos's Series E funding, gaining access to its AI platform. Pathos will use the dataset to analyze disease biology and inform clinical trials.

Pathos AI partnered with Bristol Myers Squibb and Tempus AI to develop AI tools for drug development in Alzheimer's and other neurological disorders. The company raised $237 million in a Series E funding round led by Bristol Myers, valuing it at $3 billion. Pathos will license data from Tempus for $55 million over five years and use its AI platform, Pathos Foundry, to study the dataset and design clinical trials. Bristol Myers gains non-exclusive access to Pathos Foundry.

Tempus AI, Inc. (TEM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 23, 2026, Tempus AI, Inc. (“Tempus”) announced that it had entered into a series of agreements with Bristol-Myers Squibb Company (“BMS”) and Pathos AI, Inc. (“Pathos”) to expand the use of Tempus’s de-identified multimodal real-world data, data

Bristol-Myers Squibb and SystImmune reported that their Phase 3 breast cancer trial met its primary endpoint. The interim results suggest the treatment's efficacy, which may impact future regulatory decisions and investor sentiment.

SystImmune and Bristol Myers Squibb (BMY) reported a 59% reduction in disease progression risk for iza-bren vs. chemotherapy in HR+/HER2- breast cancer. Trial showed 8.2m vs. 4.0m median PFS. BMY collaborates on iza-bren development outside China.

Bristol Myers Squibb reported that its drug izalontamab brengitecan reduced the risk of progression or death by 59% compared to chemotherapy in HR+/HER2- breast cancer, with a median progression-free survival of 8.2 months versus 4.0 months. The company noted that overall survival data is not yet mature.